cme
Metamizole: Indications and risks
Dtsch Arztebl Int 2026; 123: 27-34. DOI: 10.3238/arztebl.m2025.0214
;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel: Prof. Dr. med. Dr. rer. nat. Ingolf Cascorbi
Sektion für Neurologische Schmerzforschung und Therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel: Prof. Dr. med. Ralf Baron
Sektion für Neurologische Schmerzforschung und Therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel: Prof. Dr. med. Ralf Baron
| 1. | Oreskovic Z, Bicanic G, Hrabac P, Tripkovic B, Delimar D: Treatment of postoperative pain after total hip arthroplasty: Comparison between metamizol and paracetamol as adjunctive to opioid analgesics-prospective, double-blind, randomised study. Arch Orthop Trauma Surg 2014; 134: 631–6 CrossRef MEDLINE |
| 2. | Saray A, Buyukkocak U, Cinel I, Tellioglu AT, Oral U: Diclofenac and metamizol in postoperative analgesia in plastic surgery. Acta Chir Plast 2001; 43: 71–6 MEDLINE |
| 3. | Schneider T, Mauermann E, Ilgenstein B, Jaquiery C, Ruppen W: Analgesic benefit of metamizole and ibuprofen vs. either medication alone: A randomized clinical trial. Minerva Anestesiol 2022; 88: 448–56 CrossRef MEDLINE |
| 4. | Gaertner J, Stamer UM, Remi C, et al.: Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat Med 2017; 31: 26–34 CrossRef MEDLINE |
| 5. | BfArM: Rote-Hand-Brief zu metamizolhaltigen Arzneimitteln: Wichtige Maßnahmen zur Minimierung der schwerwiegenden Folgen des bekannten Risikos für Agranulozytose. www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2024/rhb-metamizol.html (last accessed on 14 June 2025). |
| 6. | Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K: Inhibition of cyclooxygenases by dipyrone. Br J Pharmacol 2007; 151: 494–503 CrossRef MEDLINE PubMed Central |
| 7. | Cecilio NT, Souza GR, Alves-Filho JC, Cunha FQ, Cunha TM: The PI3Kγ/AKT signaling pathway mediates peripheral antinociceptive action of dipyrone. Fundam Clin Pharmacol 2021; 35: 364–70 CrossRef MEDLINE |
| 8. | Goncalves Dos Santos G, Vieira WF, Vendramini PH, et al.: Dipyrone is locally hydrolyzed to 4-methylaminoantipyrine and its antihyperalgesic effect depends on CB(2) and kappa-opioid receptors activation. Eur J Pharmacol 2020; 874: 173005 CrossRef MEDLINE |
| 9. | Goncalves Dos Santos G, Li R, Ng MPE, et al.: CB(1) receptor-dependent desensitisation of TRPV1 channels contributes to the analgesic effect of dipyrone in sensitised primary sensory neurons. Br J Pharmacol 2020; 177: 4615–26 CrossRef MEDLINE PubMed Central |
| 10. | Ludwig WD, Mühlbauer B; Seifert, R.: Arzneimittelverordnungsreport 2023. Berlin: Springer 2024 CrossRef |
| 11. | Hoffmann F, Bantel C, von Rosen FT, Jobski K: Regional differences in prescribing patterns of metamizole in Germany based on data from 70 million persons. Int J Environ Res Public Health 2020; 17: 3892 CrossRef MEDLINE PubMed Central |
| 12. | Grandt D, Lappe, V., Schubert, I.: BARMER Arzneimittelreport 2023 www.barmer.de/resource/blob/1241248/8e2483171c80ba878809dfdac7ccdb8e/arzneimittelreport-2023-data.pdf (last accessed on 13 June 2025). |
| 13. | Klose S, Pflock R, Konig IR, Linder R, Schwaninger M: Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn Schmiedebergs Arch Pharmacol 2020; 393: 681–90 CrossRef MEDLINE |
| 14. | Reist L, Erlenwein J, Meissner W, Stammschulte T, Stuber F, Stamer UM: Dipyrone is the preferred nonopioid analgesic for the treatment of acute and chronic pain. A survey of clinical practice in German-speaking countries. Eur J Pain 2018; 22: 1103–12 CrossRef MEDLINE |
| 15. | Jipa M, Isac S, Klimko A, et al.: Opioid-sparing analgesia impacts the perioperative anesthetic management in major abdominal surgery. Medicina (Kaunas) 2022; 58: 487 CrossRef MEDLINE PubMed Central |
| 16. | Tempel G, von Hundelshausen B, Reeker W: The opiate-sparing effect of dipyrone in post-operative pain therapy with morphine using a patient-controlled analgesic system. Intensive Care Med 1996; 22: 1043–7 CrossRef MEDLINE |
| 17. | Peiro AM, Martinez J, Martinez E, et al.: Efficacy and tolerance of metamizole versus morphine for acute pancreatitis pain. Pancreatology 2008; 8: 25–9 CrossRef MEDLINE |
| 18. | Stessel B, Boon M, Pelckmans C, et al.: Metamizole vs. ibuprofen at home after day case surgery: A double-blind randomised controlled noninferiority trial. Eur J Anaesthesiol 2019; 36: 351–9 CrossRef MEDLINE |
| 19. | Abdulla S, Eckhardt R, Netter U, Abdulla W: A randomized, double-blind, controlled trial on non-opioid analgesics and opioid consumption for postoperative pain relief after laparoscopic cholecystectomy. Acta Anaesthesiol Belg 2012; 63: 43–50 MEDLINE |
| 20. | Ohnesorge H, Bein B, Hanss R, et al.: Paracetamol versus metamizol in the treatment of postoperative pain after breast surgery: A randomized, controlled trial. Eur J Anaesthesiol 2009; 26: 648–53 CrossRef MEDLINE |
| 21. | Soliman N, Moisset X, Ferraro MC, et al.: Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: A systematic review and meta-analysis. Lancet Neurol 2025; 24: 413–28 CrossRef MEDLINE |
| 22. | Fachinformation Metamizol AbZ 500 mg Tabletten. www.fachinfo.de/fi/pdf/013816/metamizol-abz-500-mg-tabletten (last accessed on 13 June 2025). |
| 23. | EMA: European database of suspected adverse drug reactions reports www.adrreports.eu. |
| 24. | Sabate M, Ibanez L, Perez E, et al.: Risk of acute liver injury associated with the use of drugs: A multicentre population survey. Aliment Pharmacol Ther 2007; 25: 1401–9 CrossRef MEDLINE |
| 25. | Lutz M: Metamizole (Dipyrone) and the liver: A review of the literature. J Clin Pharmacol 2019; 59: 1433–42 CrossRef MEDLINE |
| 26. | Hedenmalm K, Pacurariu A, Slattery J, Kurz X, Candore G, Flynn R: Is there an increased risk of hepatotoxicity with Metamizole? A comparative cohort study in incident users. Drug Saf 2021; 44: 973–85 CrossRef MEDLINE |
| 27. | BfArM: Rote-Hand-Brief zu Metamizol: Risiko für arzneimittelbedingten Leberschaden. www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2020/rhb-metamizol.html (last accessed on 14 June 2025). |
| 28. | Sebode M, Reike-Kunze M, Weidemann S, et al.: Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury. Br J Clin Pharmacol 2020; 86: 1406–15 CrossRef MEDLINE PubMed Central |
| 29. | Hoffmann F, Bantel C, Jobski K: Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985–2017. Basic Clin Pharmacol Toxicol 2020; 126: 116–25 CrossRef MEDLINE |
| 30. | Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J: Safety of metamizole: A systematic review of the literature. J Clin Pharm Ther 2016; 41: 459–77 CrossRef MEDLINE |
| 31. | Backstrom M, Hagg S, Mjorndal T, Dahlqvist R: Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 2002; 11: 239–45 CrossRef MEDLINE |
| 32. | Macia-Martinez MA, Castillo-Cano B, Garcia-Poza P, Martin-Merino E: Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain. Eur J Clin Pharmacol 2024; 80: 1503–14 CrossRef MEDLINE |
| 33. | EMA: Measures to minimise serious outcomes of known side effect with painkiller metamizole. www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_en.pdf (last accessed on 14 June 2025). |
| 34. | Goldstein JI, Jarskog LF, Hilliard C, et al.: Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun 2014; 5: 4757 CrossRef MEDLINE PubMed Central |
| 35. | Cismaru AL, Rudin D, Ibanez L, et al.: Genome-wide association study of Metamizole-induced agranulocytosis in European populations. Genes (Basel) 2020; 11: 1275 CrossRef MEDLINE PubMed Central |
| 36. | Caraco Y, Zylber-Katz E, Fridlander M, Admon D, Levy M: The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. Eur J Clin Pharmacol 1999; 55: 475–8 CrossRef MEDLINE |
| 37. | Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, et al.: Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2. Clin Pharmacol Ther 2021; 109: 1505–16 CrossRef MEDLINE PubMed Central |
| 38. | Watermeyer F, Gaebler AJ, Neuner I, et al.: Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine. Br J Clin Pharmacol 2024; 90: 2793–801 CrossRef MEDLINE |
| 39. | FDA: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. |
| 40. | Dannenberg L, Petzold T, Achilles A, et al.: Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients. Eur J Clin Pharmacol 2019; 75: 13–20 CrossRef MEDLINE |
| e1. | Eleuterio OHP, Veronezi RN, Martinez-Sobalvarro JV, et al.: Safety of metamizole (dipyrone) for the treatment of mild to moderate pain-an overview of systematic reviews. Naunyn Schmiedebergs Arch Pharmacol 2024; 397: 8515–25 CrossRef MEDLINE |
| e2. | Stammschulte T, Ludwig WD, Muhlbauer B, Bronder E, Gundert-Remy U: Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012. Eur J Clin Pharmacol 2015; 71: 1129–38 CrossRef MEDLINE |